Bioeq announced that it signed a license and development agreement with Coherus BioSciences, under which Coherus will exclusively market and distribute Bioeq’s biosimilar candidate to Lucentis (ranibizumab) in the United States. Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing tools and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace.
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs, marketing and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.